Free and total plasma, granulocyte and mononuclear cell colchicine concentrations were measured by radioimmunoassay in 30 patients with familial Mediterrannean fever treated with colchicine 0.5 to 2 mg day-'. Colchicine concentrations showed a large intersubject variability in plasma (0.13-1.75 ng ml-'), granulocytes (4 to 64 ng/109 cells), and mononuclear cells (11.4 to 57.6 ng/109 cells). Whereas unbound and total plasma colchicine concentrations were well correlated, no correlation was found between total or free plasma and granulocyte or mononuclear cell colchicine concentrations and dose of administered colchicine. In contrast, total or free plasma and granulocyte or mononuclear cell colchicine concentrations were correlated using a hyperbolic function indicating saturable colchicine distribution in both leukocyte populations.
Introduction
Familial Mediterranean fever (FMF) is an autosomal recessive inherited disorder that occurs in Sephardic Jews, Armenians and other ethnic groups of Mediterranean origin. The disease is characterized by selflimited inflammatory attacks. Amyloidisis occurs in a substantial proportion of patients and may lead to renal failure [1] . Continuous prophylaxis with colchicine is effective in the prevention or reduction of intensity of attacks in most patients [2] . However, unexplained partial or non-response to colchicine may be observed and increasing colchicine dosage is frequently not effective [1] . During colchicine therapy a significant decrease in granulocyte chemotaxis has been observed in FMF patients during attacks [3] . The finding of prolonged colchicine persistence in leukocytes was recently described and leukocytes were proposed as a microcompartment. The kinetics may correlate with the onset of action of colchicine and reactivation of disease following cessation of colchicine [4] . In this study we measured free and total colchicine concentration in plasma, and in granulocyte and mononuclear cells in patients with FMF on long-term colchicine treatment, in order to determine whether alterations in colchicine distribution in the leukocyte effector compartment could be pro- heparinized blood by centrifugation (3000 g, 20 min) and stored at -20°C until assayed. Granulocytes and mononuclear cells were separated immediately and lysed by three cycles of freezing and thawing for colchicine determination [4] .
Free plasma colchicine
Plasma was dialyzed (16 h, 370 C) against isotonic phosphate buffer in a system consisting of two 0.2 ml Teflon dialysis cells (Dianorm, B. Braun ScienceTec, Les Ulis, France) separated by a semipermeable membrane (M, cut-off 12,000, Union Carbide, Chicago, I1).
Analytical methods
Colchicine concentrations were measured in plasma, dialysate and cell lysate by a radioimmunoassay as previously described [4] .
Statistical analysis
Results are expressed as the mean of triplicate determinations. The differences between free and total plasma, granulocyte and mononuclear colchicine concentrations according to the daily dose were analyzed using the non-parametric Mann-Whitney rank-sum test. Linear or non-linear relationships between total or free plasma and cellular concentrations were calculated using a non-linear regression program (MKMODEL, Biosoft, Cambridge, UK). The degree of association between the observed and calculated values was analyzed using the Pearson and Spearman rho correlation coefficients.
Results
No significant correlation (P = 0.05) was observed between plasma colchicine concentration and daily dose (Figure la) . At the most common dosage, 1 mg day-', the plasma concentration ranged from 0.13 to 1.75 ng ml-'. The unbound plasma colchicine concentration (n = 22) ranged from 35 to 56% and was significantly correlated with total plasma colchicine (P < 0.001). Leukocyte colchicine concentrations exhibited the same intersubject variability (Figure lb,   1c ) and no linear relationship between intracellular concentration and dosage was found (P = 0.05). Granulocyte and mononuclear colchicine concentrations varied from 4 to 64 ng/109 cells and from 11.4 to 57.6 ng/109 cells, respectively. Figure 2 shows that when total or free plasma colchicine increased, the intracellular level for both leukocyte populations also increased but tended to a plateau. The best mathematical function fit for both cell populations was a hyperbolic function (P = 0.01) whether for total or free plasma colchicine. 
Discussion
Continuous colchicine therapy is effective in most FMF patients. Nevertheless, 15% of patients do not respond adequately [1] . Katz et al. [5] reported higher plasma colchicine in responders (2.5 ± 0.3 ng ml-') than in non-responders (0.9 ± 0.2 ng ml-'), each patient group receiving 1 mg day-' orally. However, many of the responders had levels in the nonresponder range, and Halkin et al. [6] reported that some non-responders had adequate or even higher plasma colchicine. As clinical state and plasma kinetics were poorly correlated, both studies concluded that colchicine investigation in leukocytes might be the clue to understanding its clinical effect.
Our study clearly indicates a large intersubject variability in total or free plasma, mononuclear cell and granulocyte colchicine concentrations. Determination of the unbound plasma colchicine which was closely correlated with plasma colchicine demonstrates that variability of colchicine binding to plasma proteins is not the source of intracellular colchicine inter-subject variability.
The main source of plasma colchicine concentration variability could be related to the extent of colchicine absorption which has been reported to range from 20 to 80% [7] . As the plasma level represents the bioavailable colchicine for cellular uptake, a parallel intersubject variability was observed with the intracellular colchicine level in the white blood cell populations. A second explanation could result from the observed saturable colchicine distribution in both leukocyte populations. We have previously shown using human lymphocytes in culture a slow and saturable colchicine uptake suggesting that colchicine accumulation into the cell is not due to simple equilibrium [4] . Further investigation of limited colchicine uptake in leukocytes is required especially in cells from FMF patients.
This large intersubject variability in plasma and leukocytes could explain the failure to respond to colchicine in some FMF patients. Our data thus preclude non-response to colchicine therapy being related to uncorrelated plasma and cellular levels and particularly to low intraleukocyte levels.
